MLYS
Mineralys Therapeutics, Inc. NASDAQ Listed Feb 10, 2023$29.35
Mkt Cap $1.9B
52w Low $12.59
47.8% of range
52w High $47.65
50d MA $27.20
200d MA $31.22
P/E (TTM)
-12.8x
EV/EBITDA
-13.4x
P/B
3.1x
Debt/Equity
0.0x
ROE
-23.9%
P/FCF
-17.2x
RSI (14)
—
ATR (14)
—
Beta
0.69
50d MA
$27.20
200d MA
$31.22
Avg Volume
1.2M
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
CIK (SEC)
Phone
888-378-6240
150 N. Radnor Chester Rd. · Radnor, PA 19087 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.51 | -0.47 | +7.8% | 30.12 | -3.1% | -2.6% | — | — | — | — | — |
| Mar 12, 2026 | AMC | -0.52 | -0.40 | +22.5% | 26.99 | -4.4% | -3.0% | -1.8% | -2.8% | -4.5% | -2.6% | — |
| Nov 10, 2025 | AMC | -0.66 | -0.52 | +21.2% | 44.50 | -6.0% | +5.9% | +0.5% | -6.4% | -7.8% | +8.3% | — |
| Aug 12, 2025 | AMC | -0.78 | -0.66 | +15.4% | 13.51 | -3.0% | +0.4% | +4.2% | +2.8% | +5.6% | -5.7% | — |
| May 12, 2025 | AMC | -1.02 | -0.79 | +22.5% | 15.01 | +0.4% | +1.2% | -0.5% | +1.7% | -0.1% | -0.2% | — |
| Feb 12, 2025 | AMC | -1.00 | -0.98 | +2.0% | 10.63 | -4.5% | -4.0% | +0.4% | -6.2% | -2.9% | +2.3% | — |
| Nov 11, 2024 | AMC | -0.83 | -1.13 | -36.1% | 14.92 | -9.5% | -10.3% | -7.0% | -2.2% | -5.7% | -0.7% | — |
| Aug 13, 2024 | AMC | -0.73 | -0.83 | -13.7% | 11.83 | -5.7% | -22.8% | +6.9% | +0.5% | +8.3% | -0.9% | — |
| May 9, 2024 | AMC | -0.68 | -0.70 | -2.9% | 14.27 | -1.5% | -5.3% | -4.4% | +1.0% | +0.1% | +0.6% | — |
| Mar 21, 2024 | AMC | -0.85 | -0.61 | +28.2% | 13.09 | -0.1% | -1.9% | +0.6% | -0.6% | -0.5% | +1.0% | — |
| Nov 7, 2023 | AMC | -0.72 | -0.57 | +20.8% | 8.75 | +0.0% | -6.7% | -9.3% | -12.8% | -1.4% | +12.4% | — |
| Aug 7, 2023 | AMC | -0.83 | -0.31 | +62.7% | 12.50 | -0.5% | +7.0% | -1.0% | -0.8% | -2.4% | +3.4% | — |
| May 15, 2023 | AMC | -0.71 | -0.51 | +28.2% | 16.19 | +4.8% | -4.6% | +3.7% | -1.0% | -2.2% | +2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | TD Cowen | Initiates | Buy | — | $27.51 | $28.05 | +2.0% | -1.9% | -4.1% | -1.3% | +4.3% | +9.8% |
| Mar 13 | BofA Securities | Maintains | Buy → Buy | — | $26.99 | $25.81 | -4.4% | -3.0% | -1.8% | -2.8% | -4.5% | -2.6% |
| Dec 19 | Stifel | Maintains | Buy → Buy | — | $37.00 | $37.35 | +0.9% | -0.5% | +2.0% | -0.6% | +0.2% | -0.8% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.11 | $47.23 | +0.3% | +0.5% | -6.4% | -7.8% | +8.3% | -2.0% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $44.50 | $41.81 | -6.0% | +5.9% | +0.5% | -6.4% | -7.8% | +8.3% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.14 | $40.97 | +2.1% | +2.4% | -0.6% | -4.1% | +1.6% | -0.4% |
| Sep 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $38.56 | $38.99 | +1.1% | -3.6% | -0.2% | -2.4% | +3.3% | -0.3% |
| Sep 9 | Goldman Sachs | Maintains | Buy → Buy | — | $35.93 | $36.68 | +2.1% | +7.2% | +0.2% | -3.6% | -0.2% | -2.4% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $34.84 | +0.1% | +3.2% | +7.2% | +0.2% | -3.6% | -0.2% |
| Sep 3 | Jefferies | Maintains | Hold → Hold | — | $28.86 | $28.00 | -3.0% | +1.4% | +13.2% | +5.1% | +3.2% | +7.2% |
| Aug 28 | BofA Securities | Maintains | Buy → Buy | — | $15.21 | $15.47 | +1.7% | +0.1% | +1.7% | +86.4% | +1.4% | +13.2% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.51 | $13.11 | -3.0% | +0.4% | +4.2% | +2.8% | +5.6% | -5.7% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.45 | $13.70 | +1.9% | +2.5% | -0.4% | -1.8% | +2.2% | +2.7% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.01 | $15.07 | +0.4% | +1.2% | -0.5% | +1.7% | -0.1% | -0.2% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.84 | $13.85 | +0.1% | +1.2% | -3.4% | -8.4% | -2.8% | -2.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.52 | $14.13 | +34.3% | +42.2% | -4.4% | -8.3% | +3.0% | +5.6% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $9.56 | $9.54 | -0.2% | -3.2% | -5.3% | +10.5% | +2.9% | -8.2% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.63 | $10.15 | -4.5% | -4.0% | +0.4% | -6.2% | -2.9% | +2.3% |
| Feb 13 | Goldman Sachs | Maintains | Buy → Buy | — | $10.63 | $10.15 | -4.5% | -4.0% | +0.4% | -6.2% | -2.9% | +2.3% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.92 | $13.51 | -9.5% | -10.3% | -7.0% | -2.2% | -5.7% | -0.7% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.78 | $13.48 | -2.2% | -2.9% | +0.5% | +0.4% | +0.1% | +10.7% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.13 | $9.33 | +2.2% | +6.9% | +0.5% | +8.3% | -0.9% | +5.9% |
| Aug 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $12.50 | $12.44 | -0.5% | +7.0% | -1.0% | -0.8% | -2.4% | +3.4% |
| May 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $16.19 | $16.97 | +4.8% | -4.6% | +3.7% | -1.0% | -2.2% | +2.2% |
| Mar 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $16.35 | $16.37 | +0.1% | -5.9% | +0.4% | -3.8% | -2.8% | -0.5% |
No insider trades available.
8-K · 2.02
!! High
Mineralys Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Mineralys Therapeutics reported Q1 2026 financial results and provided a corporate update, giving investors insight into the company's operational performance and strategic direction.
May 6
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Multiple executive departures at IMUX and MLYS effective March 27, 2026, signal potential leadership instability that could disrupt strategic execution and warrant caution on both stocks.
Mar 31
8-K
Unknown — 8-K Filing
Mineralys achieved a major regulatory milestone with FDA acceptance of its lead hypertension drug's application, potentially enabling market entry by late 2026 and substantially increasing shareholder value if approved.
Mar 12
8-K · 8.01
!! High
Mineralys Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Mineralys Therapeutics' lorundrostat hypertension drug NDA received FDA acceptance with a December 2026 decision deadline, advancing the candidate toward potential market approval.
Mar 9
Data updated apr 26, 2026 12:39pm
· Source: massive.com